FOLH1 and prostate cancer: Although these studies describe patients with oligometastatic prostate cancer, we present a case of up-front [177Lu]Lu-PSMA-617 administered to an individual with greater disease burden, including significant abdominopelvic metastatic lymphadenopathy and an osseous metastasis, who did not receive any initial local therapy to the prostate.